Epidural Morphine
Phase 3Small molecule
Epidural Morphine is one of 21 small molecule programs targeting Analgesia. It is currently in Phase 3.
1
Indications
4
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
22 competitors in Analgesia
#DrugCompanyPhaseTrials
1Sufenta
LLeaf Vertical Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Penthrane
PPurdue Pharma, Canada
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Oxycontin
PPurdue Pharma LP
Phase 3
Intrathecal Morphine
Pacira Pharmaceuticals, IncPhase 3
Bupivacaine Liposome
Pacira Pharmaceuticals, IncPhase 3
Esketamine Combined With Dexmedetomidine
TThe First Affiliated Hospital with Nanjing Medical University
Phase 3
Marcaine
IInnocoll
Phase 1
Narcan
SScienture
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Analgesia2 trials
Two Dose Epidural Morphine for Post-cesarean Analgesia
Terminated·—·Phase 4·NCT01844206·5 enrolled
Epidural1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Epidural Morphine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Colorado, Denver